Dabigatran, rivaroxaban, apixaban, argatroban and fone coagulation POC and platelet function tests

Clinical Chemistry and Laboratory Medicine 52, 835-44 DOI: 10.1515/cclm-2013-0936

Citation Report

#	Article	IF	CITATIONS
1	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. Clinics in Laboratory Medicine, 2014, 34, 479-501.	1.4	29
2	A critical appraisal of pointâ€ofâ€care coagulation testing in critically ill patients. Journal of Thrombosis and Haemostasis, 2015, 13, 1960-1967.	3.8	65
3	Usefulness of Platelet Function Tests to Predict Bleeding With Antithrombotic Medications. Cardiology in Review, 2015, 23, 323-327.	1.4	5
4	Viscoelastic Methods of Blood Clotting Assessment – A Multidisciplinary Review. Frontiers in Medicine, 2015, 2, 62.	2.6	43
5	UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS ONE, 2015, 10, e0145478.	2.5	35
6	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) Tj ETQq1 1	0.7894314	rg B⁄T /O verlo
7	Comparison of fondaparinux sodium and low molecular weight heparinÂinÂtheÂtreatment of hypercoagulability secondary to traumatic infection. Chinese Journal of Traumatology - English Edition, 2015, 18, 147-149.	1.4	3
8	Impact of dabigatran on platelet function and fibrinolysis. Journal of the Neurological Sciences, 2015, 357, 204-208.	0.6	10
9	Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. Seminars in Thrombosis and Hemostasis, 2015, 41, 208-227.	2.7	95
10	Global assays and the management of oral anticoagulation. Thrombosis Journal, 2015, 13, 9.	2.1	48
11	Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 531-536.	1.2	4
12	Point-of-Care Testing of Coagulation in Patients Treated With Non–Vitamin K Antagonist Oral Anticoagulants. Stroke, 2015, 46, 2741-2747.	2.0	62
13	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Thrombosis and Haemostasis, 2016, 115, 622-631.	3.4	23
15	Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation. Medicine (United States), 2016, 95, e3037.	1.0	18
16	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. Science Translational Medicine, 2016, 8, 367ra168.	12.4	32
17	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets, 2016, 27, 687-693.	2.3	16
18	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Critical Care, 2016, 20, 273.	5.8	19
19	Whole Blood Assay: Thromboelastometry. , 2016, , 37-64.		7

#	Article	IF	CITATIONS
20	Periprocedural Management of Novel Oral Anticoagulants During Atrial Fibrillation Ablation: Controversies and Review of the Current Evidence. Heart Lung and Circulation, 2016, 25, 1164-1176.	0.4	8
21	TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thrombosis Research, 2016, 138, 63-68.	1.7	31
22	Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. Journal of Thrombosis and Thrombolysis, 2016, 42, 161-166.	2.1	21
23	Assessment of the Effects of Antithrombotic Drugs. , 2016, , 173-192.		0
25	Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran. Clinica Chimica Acta, 2017, 466, 20-21.	1.1	3
26	Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 1522-1523.	3.8	1
27	Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. Journal of Thrombosis and Thrombolysis, 2017, 44, 216-222.	2.1	23
28	Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment. Thrombosis Research, 2017, 153, 76-82.	1.7	28
29	Impact of rivaroxaban on point-of-care assays. Thrombosis Research, 2017, 153, 65-70.	1.7	26
30	Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art. Seminars in Thrombosis and Hemostasis, 2017, 43, 423-432.	2.7	22
31	The use of frozen plasma samples in thromboelastometry. Clinical and Experimental Medicine, 2017, 17, 489-497.	3.6	12
32	Direct oral anticoagulants and heparins: laboratory values and pitfalls in â€~bridging therapy'. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw368.	1.4	7
33	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	2.8	285
34	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, e24-e27.	1.3	15
35	Practical Use of Thromboelastometry in the Management of Perioperative Coagulopathy and Bleeding. Transfusion Medicine Reviews, 2017, 31, 11-25.	2.0	36
36	Optimal Reversal of Novel Anticoagulants in Trauma. Critical Care Clinics, 2017, 33, 135-152.	2.6	10
37	Measurement and reversal of the direct oral anticoagulants. Blood Reviews, 2017, 31, 77-84.	5.7	133
38	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. Chest, 2017, 151, 127-138.	0.8	245

CITATION REPORT

			2
#	ARTICLE	IF	CITATIONS
39	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management, 2017, Volume 13, 457-467.	2.3	40
40	Optical sensing of anticoagulation status: Towards point-of-care coagulation testing. PLoS ONE, 2017, 12, e0182491.	2.5	20
41	Viscoelastic testing inside and beyond the operating room. Journal of Thoracic Disease, 2017, 9, S299-S308.	1.4	50
42	Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants. Thrombosis Research, 2018, 165, 101-106.	1.7	23
43	Outcomes of Early Surgical Intervention in Geriatric Proximal Femur Fractures Among Patients Receiving Direct Oral Anticoagulation. Journal of Orthopaedic Trauma, 2018, 32, 269-273.	1.4	36
44	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Thrombosis Research, 2018, 163, 100-104.	1.7	11
45	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 2018, 120, 645-656.	3.4	115
46	Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry – a prospectively controlled randomized double-blind clinical trial. BMC Anesthesiology, 2018, 18, 18.	1.8	25
49	Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). International Journal of Laboratory Hematology, 2018, 40, 84-93.	1.3	59
50	Secondary Gains. Emergency Medicine Clinics of North America, 2018, 36, 107-133.	1.2	15
51	Con: Activated Clotting Time Should Not Be Monitored During Heparinization for Vascular Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1497-1499.	1.3	2
52	Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombinâ€based trigger. Journal of Thrombosis and Haemostasis, 2018, 16, 2462-2470.	3.8	13
53	Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 194S-201S.	1.7	8
54	Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory. JACC: Cardiovascular Interventions, 2018, 11, 1775-1778.	2.9	5
55	Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays. Clinica Chimica Acta, 2018, 486, 347-356.	1.1	27
56	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1199-1207.	1.7	28
57	Rivaroxaban May Increase Platelet Activation In Vivo via Thromboxane A2. Circulation Research, 2019, 125, e9.	4.5	5
58	Head Trauma. , 2019, , 87-104.		Ο

CITATION REPORT

#	Article	IF	CITATIONS
59	Vascular proteaseâ€activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by longâ€ŧerm dabigatran administration – results from a diabetes animal model. Journal of Thrombosis and Haemostasis, 2019, 17, 538-550.	3.8	8
60	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961984752.	1.7	19
61	The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation. Thrombosis and Haemostasis, 2019, 119, 916-929.	3.4	14
62	Pharmacological strategies for targeting platelet activation in asthma. Current Opinion in Pharmacology, 2019, 46, 55-64.	3.5	22
63	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. European Journal of Anaesthesiology, 2019, 36, 449-456.	1.7	22
64	Advances in monitoring anticoagulant therapy. Advances in Clinical Chemistry, 2019, 90, 197-213.	3.7	9
65	Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients. Journal of Thrombosis and Thrombolysis, 2019, 47, 272-279.	2.1	10
66	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. Platelets, 2020, 31, 43-47.	2.3	3
67	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 594-622.	2.8	187
68	Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. Journal of Arrhythmia, 2020, 36, 644-651.	1.2	2
69	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. Leukemia and Lymphoma, 2020, 61, 3422-3431.	1.3	1
70	Point-of-Care Hematology. , 2020, , 123-138.		0
71	Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation. Thrombosis Research, 2020, 191, 38-41.	1.7	2
72	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 424.	2.4	4
73	Reversing the Effect of Anticoagulants Safety in Patients Undergoing Emergency Surgery. Hot Topics in Acute Care Surgery and Trauma, 2021, , 79-95.	0.1	0
74	ROTEM Testing for Direct Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2021, 47, 815-823.	2.7	9
75	Impact of Dabigatran Treatment on Rotation Thromboelastometry. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962098390.	1.7	8
76	Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran. Thrombosis and Haemostasis, 2021, 121, 782-791.	3.4	5

#	Article	IF	CITATIONS
77	Thermally driven formation of polyphenolic carbonized nanogels with high anticoagulant activity from polysaccharides. Biomaterials Science, 2021, 9, 4679-4690.	5.4	9
78	Rotational Thromboelastometry (ROTEM®). , 2016, , 267-298.		28
79	Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase. PLoS ONE, 2016, 11, e0149077.	2.5	4
80	Klinisch-chemische Diagnostik in der AnÄsthesiologie. , 2016, , 1-30.		0
81	Klinisch-chemische Diagnostik in der AnÄ s thesiologie. Springer Reference Medizin, 2019, , 591-619.	0.0	0
82	Rotational Thromboelastometry (ROTEMÂ $^{\circ}$). , 2021, , 279-312.		3
83	Reversal of anticoagulation in neurosurgical and neurocritical care settings. , 2022, , 239-266.		0
84	Pre- and Perioperative Management of Hip Fracture. , 2022, , 483-494.		0
85	"In Less than No Time― Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy. Journal of Clinical Medicine, 2022, 11, 1407.	2.4	14
86	Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban. Journal of Cardiovascular Development and Disease, 2022, 9, 205.	1.6	1
87	Towards 50 years of platelet function analyser (PFA) testing. Clinical Chemistry and Laboratory Medicine, 2023, 61, 851-860.	2.3	10
88	Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. TH Open, 2022, 06, e238-e247.	1.4	2
89	The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochemical Journal, 2022, 479, 1653-1708.	3.7	27
90	Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function. Toxicologic Pathology, 0, , 019262332211292.	1.8	0
91	Recent advances in laboratory hematology reflected by a decade of <i>CCLM</i> publications. Clinical Chemistry and Laboratory Medicine, 2022, .	2.3	1
92	Platelets and Their Role in Hemostasis and Thrombosis—From Physiology to Pathophysiology and Therapeutic Implications. International Journal of Molecular Sciences, 2022, 23, 12772.	4.1	16
93	The impact of direct oral anticoagulants on viscoelastic testing – A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	8
94	The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396, 337-351.	3.0	2

CITATION REPORT

#	Article	IF	CITATIONS
95	Impact of surface coating and systemic anticoagulants on hemostasis and inflammation in a human whole blood model. PLoS ONE, 2023, 18, e0280069.	2.5	1
96	Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100083.	2.3	1
97	Comparative Analysis of Roots from Vicatia thibetica de Boiss and Angelica sinensis Based on Chemical Composition, Antioxidant, Nitrite-Scavenging and Enzyme Inhibition Activities. Molecules, 2023, 28, 1942.	3.8	1
98	Immature platelets in COVID-19. Platelets, 2023, 34, .	2.3	4
99	Pharmacological methods for blood stabilization in the extracorporeal circuit (review of literature). Messenger of Anesthesiology and Resuscitation, 2023, 20, 81-88.	0.6	0
101	Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition). Cardiology Plus, 2024, 9, 49-69.	0.7	0